AU732671B2 - Method of treatment and pharmaceutical composition - Google Patents

Method of treatment and pharmaceutical composition Download PDF

Info

Publication number
AU732671B2
AU732671B2 AU22579/97A AU2257997A AU732671B2 AU 732671 B2 AU732671 B2 AU 732671B2 AU 22579/97 A AU22579/97 A AU 22579/97A AU 2257997 A AU2257997 A AU 2257997A AU 732671 B2 AU732671 B2 AU 732671B2
Authority
AU
Australia
Prior art keywords
phenyl
sodium
pharmaceutical formulation
loratadine
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU22579/97A
Other versions
AU2257997A (en
Inventor
Sven-Erik Dahlen
Edward M. Scolnick
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9608927.1A external-priority patent/GB9608927D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2257997A publication Critical patent/AU2257997A/en
Application granted granted Critical
Publication of AU732671B2 publication Critical patent/AU732671B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Description

MAR. 2061 16:12 SPRUSON AND FERGUSON 61292515486 NO, 1161 P. 11 Method of Treatment and Pharmaceutical Composition Background of the Invention Loratadine is an antihistamine with H-receptor antagonist properties useful in the treatment of allergies and is described in US 4,282,233.
Leukotriene antagonists are known to be useful in the treatment of asthma, allergic reactions, and inflammxation.
Now with the present invention, there is provided a method of treatment asthma, allergy and inflammation with a combination of these two agents which is more efficacious than either agent by itself.
Summary of the Invention This invention is concerned with a pharmaceutical formulation comprising as active ingredients loratadine and a leukotrine antagonist; and a method of treatment of asthma, allergy or inflammation by administration of an effective amount of loratadine and an effective amount of a leukotriene antagonist either by essentially concurrent administration or combined in a single pharmaceutical composition wherein the leukotriene antagonist is selected from: A. Sodium 1 -(((R)-(3-(2-(7-chloro-2-quinolinyl)effienyl)phenyl)-3- 2 2 -hydroxy-2-propyl)phenyl)tbio)methyl)cyclopropane acetate, EP 480,717 0 ONa zo Montelukast Sodium B. Sodium I 3 2 6 7 -difluoro-2-quinolinyl)ethenyl)pheyl..3- 2 2 -hydroxy-2-propyl)phenyl)thio)methyl)cyclopropane acetate. US 5,270,324 [RfiUSMVVj02308.doaenjc 05/03 '01 MON 16:01 [TX/RX NO 8463] 2001 16:12 SPRUSON AND FERGUSON 61292615486 NO. 1161 P. 12 C. I -dirhlorotbieno[3,2-b]pyridin-5.yl)-(E)-ethenyl)phenyl).
-hydroxy- 1-mnethyl ethyl)phenyl)-propyl)thio)methyl) cyclopropane acetic acid or sodium salt thereof US 5,472,964 D. N-[4-oxo-2"(1H-tetraazol-5-yl)41--1 -benzopyran-8-yJ]-p- (4-phenylbutoxy)benzarnide. EP 173,516 0** .0.0 Pranlukast E, Cyclopentyl-3-[2.meth 'oxy-4-[(otolysulfonyl)carbamoy1]..bezyl]. 1- IQ) methylindole-S-carbaznate. EP 199,543 Za0ruks Th islsreo hepeen nvnin hrfoeiclds monteluast sodium sodium 1 -(((R)-(3-(2-(6,7-difluoro-2-quinolnyl)ethenyl)phenyl..3-(2.
2 -hydroxy-2.-propyl)phenyl)thio)methylcyclopropane acetate; 1 -dichlorothiieno[3,2-b]pyridin-5 etbeflyl)phenyl)-3-(2-(1 -hydroxy- 1- rnethylethyl)phenyl)propyl)tbio)methyl)cyclopropane acetic acid or a sodium salt thereof; KRALJ9VVO2308,doc-njc 05/03 '01 MON 16:01 [TX/RX NO 8463] 5.MAR.2001 16:12 SPRUSON AND FERGUSON 61292615486 NO, 1161 P. 13 2a pranlukast; and zafirlukast; and a pharmaceutically acceptable carrier; A method of treating asthma, allergy or inflammation in a patient by the s administration of an effective amount of loratadine and an effective amount of a leukotriene antagonist selected from: montelukast sodium; sodium 7-difluoro-2-quinolinyl)ethenyl)phenyl) 2 -hydroxy-2-propyl)phenyl)thio)methyl)cyclopropane acetate; 1o 1 (R)-(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5yl)(.)ethenyl)phenyl)-3-(2-(1-hydroxy-l -methylethyl)phenyl)propyl)thio)methyl)cyclopropanacetic acid or a sodium salt thereof, pranlukast; and zafirlukast; .15 either substantially concurrently in separate dosage forms or combined in the i:l .single pharmaceutical formulation of that described above; An effective amount of loratadine and an effective amount of a leukotriene antagonist selected from: montelukast sodium; sodium I -(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)3-(2.
(2-hydrxy-2-propyl)phnyl)to)methyi)cyclopropane acetate; 1-(((1(R)-(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)ethenyl)phenyl)-3(2-( l -hydroxy- l-methylethyl)phenyl)propyl)thio)methyl)cyclopropaneacetic acid or a sodium salt thereof; pranlukast; and zafirlukast; either substantially concurrently in separate dosage forms or combined in the single pharmaceutical formulation of that described above, when used in the treatment or prophylaxis of asthma, allergy or inflammation; and Use of an effective amount of loratadine and an effective amount of a leukotriene antagonist selected from: montelukast sodium; sodium 3 2 6 ,7-difluororo-2-quinoliyl)ethenyl)phenyl) 3-(2- 2 -hydroxy-2-propyl)phenyl)thio)methyI)cyclop pane acetate; [LALIAVVj02308doc:njc 05/03 '01 MON 16:01 [TX/RX NO 8463] 5.MAR.2001 16:13 SMAR.2081 6:13SPRUSON AND FERGUSON 61292615486 N,16 .1 NO. 1161 P. 14 1 (R)-(3-(2-(2,3-dichlorothieno[3 ethenyl)phenyl)-3-(2-(l -hydroxy-1 -methylethyl)phenyl)propyl)tbio)rnethyl)cyclopropaneacetic acid or a sodium salt thereof; pranlukast; and zafirlukast;, for the manufacture of a muedicamnent for the treatment of asthma, allergy or inflammation.
Detailed Description of the Invention The novel Pharmaceutical composition of this invention comprises a combiniation of loratadine and a leukotriene antagonist selected fromn A, B, C, D and E, described above, as active ingredients, and optionally a pharmaceutically acceptable. carrier suitable for enteral or parenteral administration. The formulations may be in solid form, as for example tablets and capsules, or in liquid form, as for a.
a a a (RA\1BV'V)02308.doc~njc 05/03 '01 MON 16:01 [TX/RX NO 84631 example, syrups, elixirs, emulsions and injectables. In the formulation of pharmaceutical dosage forms there generally is utilised excipients such as water, gelatin, lactose starches, magnesium stearate, talc, vegetable oils, benzyl alcohol, gums, polyalkylene glycols, and petroleum jelly. A preferred formulation is mere fully described in the following Example.
In the novel method of treatment of this invention, the loratadine and leukotriene antagonist can be administered substantially concurrently as separate dosage forms or combined in the novel pharmaceutical formulation of this invention.
Although the required dosage will be determined by such factors as the patients age, sex, weight and severity of the condition being treated, the preferred human oral dosage range is about 5 to 20mg, loratadine, 1 to 3 times per day; preferably about 10mg once a day. In the case of the leukotrienes, the human dosage range is also about 5 to 20mg 1 to 3 times per day; preferably about once a day.
15 Example Montelukast Sodium 10mg and Loratadine 10mg Film Coated Tablet *6
C@
SS
S. 0 C C
C.
OS
S
S.
0@Oe 0S *0 0
SOC.
0 0O C 0@
S
005 Amt. Per Tablet Ingredient Core 10.4mg Montelukast Sodium 10.0mg Loratadine 66.6mg Microcrystalline Cellulose, NF 100.0mg Lactose Monohydrate, NF Croscarmellose Sodium, NF (60.0mg) Purified Water, USP 1.0mg Magnesium Stearate, NF 200.0mg Core Tablet Film Coating 2.25mg Hydroxypropyl Methylcellulose 6cps 1.25mg Hydroxypropyl Cellulose LF 1.50mg Titanium Dioxide (33.5)mg Purified Water 205.0mg Film Coated Tablet Aa5001

Claims (19)

1. A pharmaceutical formulation comprising as active ingredients loratadine and a leukotriene antagonist selected from montelukast sodium; sodium 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2- (2-hydroxy-2-propyl)phenyl)thio)methylcyclopropane acetate; 1-(((1(R)-(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)- ethenyl)phenyl)-3-(2-(1-hydroxy-1- methylethyl)phenyl)propyl)thio)methyl)cyclopropane acetic acid or a sodium salt thereof; pranlukast; and zafirlukast; and a pharmaceutically acceptable carrier.
2. The formulation of claim 1 which is designed for oral administration.
3. The formulation of claim 2 comprising 10mg of loratadine and 10mg of a leukotriene antagonist selected from and
4. The formulation of claim 1, wherein the leukotriene antagonist is montelukast sodium. Go
5. The formulation of claim 4, which is designed for oral administration.
6. The formulation of claim 5, comprising 10mg of each active ingredient. 20
7. A pharmaceutical formulation, substantially as hereinbefore described with reference to the example.
8. A method of treating asthma, allergy or inflammation in a patient by the administration of an effective amount of loratadine and an effective amount of a S leukotriene antagonist selected from: 25 montelukast sodium; sodium 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2- o.;o (2-hydroxy-2-propyl)phenyl)thio)methyl)cyclopropane acetate; 1-(((1(R)-(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)- ethenyl)phenyl)-3-(2-(1-hydroxy-1 -methylethyl)- phenyl)propyl)thio)methyl)cyclopropaneacetic acid or a sodium salt thereof; pranlukast; and zafirlukast; either substantially concurrently in separate dosage forms or combined in the Asingle pharmaceutical formulation of any one of claims 1 to 7. [R:\LIBAA]8645.doc:njc
9. The method of claim 8, wherein the pharmaceutical formulation is designed for oral administration.
The method of claim 9, wherein the separate dosage forms and the single pharmaceutical formulation comprise 10mg of loratadine and 10mg of a leukotriene antagonist selected from and
11. The method of claim 10, wherein the leukotriene antagonist is (A) montelukast sodium.
12. The method of claim 11, wherein the separate dosage forms and single pharmaceutical formulation are designed for oral administration.
13. The method of claim 12, wherein the separate dosage forms and the single pharmaceutical formulation comprise 10mg of loratadine and 10mg of montelukast sodium.
14. An effective amount of loratadine and an effective amount of a leukotriene antagonist selected from: montelukast sodium; sodium 1-(((R)-(3-(2-(6,7-difluoro-2-quinolinyl)ethenyl)phenyl)-3-(2- (2-hydroxy-2-propyl)phenyl)thio)methyl)cyclopropane acetate; 1-(((1(R)-(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)- ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)- 20 phenyl)propyl)thio)methyl)cyclopropaneacetic acid or a sodium salt thereof; pranlukast; and zafirlukast; either substantially concurrently in separate dosage forms or combined in .single pharmaceutical formulation of any one of claims 1 to 7, 25 when used in the treatment or prophylaxis of asthma, allergy or inflammation.
15. Use of an effective amount of loratadine and an effective amount of a leukotriene antagonist selected from: montelukast sodium; sodium 1-(((R)-(3-(2-(6,7-difluororo-2-quinolinyl)ethenyl)phenyl)-3-(2- (2-hydroxy-2-propyl)phenyl)thio)methyl)cyclopropane acetate; 1-(((l(R)-(3-(2-(2,3-dichlorothieno[3,2-b]pyridin-5-yl)-(E)- ethenyl)phenyl)-3-(2-(1-hydroxy-l-methylethyl)- phenyl)propyl)thio)methyl)cyclopropaneacetic acid or a sodium salt thereof; A pranlukast; and .AL''4 zafirlukast; [R:\LIBAA]8645.doc:njc for the manufacture of a medicament for the treatment of asthma, allergy or inflammation.
16. The use of claim 15, wherein the pharmaceutical formulation is designed for oral administration.
17. The use of claim 16, wherein the separate dosage forms and the single pharmaceutical formulation comprise 10mg of loratadine and 10mg of a leukotriene antagonist selected from and
18. The use of claim 12, wherein the leukotriene antagonist is montelukast sodium.
19. The use of claim 18, wherein the separate dosage forms and single pharmaceutical formulation are designed for oral administration. The use of claim 19, wherein the separate dosage forms and the single pharmaceutical formulation comprise 10mg of loratadine and 10mg of montelukast sodium. Dated 5 March, 2001 Merck Co., Inc. Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON *ooo* *o• [R:\LIBAA]8645.doc:njc
AU22579/97A 1996-02-08 1997-02-04 Method of treatment and pharmaceutical composition Ceased AU732671B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1132896P 1996-02-08 1996-02-08
US60/011328 1996-02-08
GBGB9608927.1A GB9608927D0 (en) 1996-04-29 1996-04-29 Method of treatment and pharmaceutical composition
GB9608927 1996-04-29
PCT/US1997/001799 WO1997028797A1 (en) 1996-02-08 1997-02-04 Method of treatment and pharmaceutical composion

Publications (2)

Publication Number Publication Date
AU2257997A AU2257997A (en) 1997-08-28
AU732671B2 true AU732671B2 (en) 2001-04-26

Family

ID=26309231

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22579/97A Ceased AU732671B2 (en) 1996-02-08 1997-02-04 Method of treatment and pharmaceutical composition

Country Status (19)

Country Link
EP (1) EP1014972A4 (en)
JP (1) JPH11504044A (en)
KR (1) KR19990082367A (en)
CN (1) CN1210465A (en)
AU (1) AU732671B2 (en)
BG (1) BG102669A (en)
BR (1) BR9707369A (en)
CA (1) CA2245162A1 (en)
CZ (1) CZ248798A3 (en)
EE (1) EE9800234A (en)
IL (1) IL125446A0 (en)
IS (1) IS4805A (en)
NO (1) NO983641L (en)
NZ (1) NZ331160A (en)
PL (1) PL328074A1 (en)
SK (1) SK105698A3 (en)
TR (1) TR199801511T2 (en)
WO (1) WO1997028797A1 (en)
YU (1) YU33298A (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214683B1 (en) 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7211582B1 (en) 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
GB9723985D0 (en) 1997-11-14 1998-01-14 Zeneca Ltd Pharmaceutical compositions
IL136461A0 (en) * 1997-12-23 2001-06-14 Schering Corp Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6194431B1 (en) 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US6384038B1 (en) 1998-04-14 2002-05-07 Sepracor Inc. Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants
US6248308B1 (en) 1998-04-14 2001-06-19 Sepracor Inc. Methods of using norastemizole in combination with leukotriene inhibitors to treat or prevent asthma
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ID29137A (en) * 1998-07-27 2001-08-02 Schering Corp HIGH AFINITY LIGANS FOR ORL-1 NOSISEPTIN RECEPTORS
PE20001070A1 (en) * 1998-09-10 2000-10-19 Schering Corp METHODS AND COMPOSITIONS TO TREAT SINUSITIS, OTITIS MEDIA AND OTHER RELATED DISORDERS USING ANTIHISTAMINES
AU3924500A (en) * 1999-03-29 2000-10-16 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
DE10007203A1 (en) 2000-02-17 2001-08-23 Asta Medica Ag Composition for treating allergic and/or vasomotor rhinitis or allergic conjunctivitis by topical or oral administration, contains synergistic combination of non-sedating antihistamine and leukotriene antagonist
AU2002227240A1 (en) * 2000-10-30 2002-05-15 Schering Corporation Treatment and method using loratadine and montelukast
US20020198228A1 (en) * 2001-04-03 2002-12-26 Kaura Sita R. Composition and method for the treatment of respiratory desease
WO2004087095A2 (en) * 2003-03-31 2004-10-14 Osmotica Costa Rica, Sociedad Anonima Osmotic controlled release device containing zafirlukast and an h1-antagonist
WO2005037245A2 (en) * 2003-10-21 2005-04-28 Direct-Haler A/S A multiple route medication for the treatment of rhinitis and asthma
WO2005089748A1 (en) * 2004-03-17 2005-09-29 Pfizer Limited Combination for treating inflammatory diseases
CA2585122A1 (en) 2004-10-25 2006-05-04 Schering Corporation M1 and/or m3 receptor antagonists in combination with other actives for treating respiratory disorders
TR200806298A2 (en) * 2008-08-22 2010-03-22 Bi̇lgi̇ç Mahmut Pharmaceutical formulation
AR077101A1 (en) 2009-06-16 2011-08-03 Schering Corp STEROIDS OF HETEROARILO (3,2-C), AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES OF THE SAME
KR101540191B1 (en) * 2014-02-24 2015-07-28 성균관대학교산학협력단 Composition comprising Loratadine for anti-inflammation
WO2020143744A1 (en) * 2019-01-10 2020-07-16 Jiangyin Mucocare Pharmaceutical Co., Ltd. New formulations containing leukotriene receptor antagonists

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282233B1 (en) * 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
CA1261835A (en) * 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
GB8607294D0 (en) * 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
US5565473A (en) * 1990-10-12 1996-10-15 Merck Frosst Canada, Inc. Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists
US5270324A (en) * 1992-04-10 1993-12-14 Merck Frosst Canada, Inc. Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists
US5472964A (en) * 1992-12-22 1995-12-05 Merck Frosst Canada, Inc. Diaryl 5,6-fused heterocyclic acids as leukotriene antagonists
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Also Published As

Publication number Publication date
EE9800234A (en) 1998-12-15
NO983641D0 (en) 1998-08-07
KR19990082367A (en) 1999-11-25
NO983641L (en) 1998-08-07
BR9707369A (en) 1999-07-20
IS4805A (en) 1998-07-22
BG102669A (en) 1999-04-30
NZ331160A (en) 2000-07-28
PL328074A1 (en) 1999-01-04
AU2257997A (en) 1997-08-28
SK105698A3 (en) 1999-05-07
EP1014972A4 (en) 2004-12-08
EP1014972A1 (en) 2000-07-05
YU33298A (en) 1999-11-22
WO1997028797A1 (en) 1997-08-14
TR199801511T2 (en) 1998-10-21
CN1210465A (en) 1999-03-10
JPH11504044A (en) 1999-04-06
CZ248798A3 (en) 1999-01-13
CA2245162A1 (en) 1997-08-14
IL125446A0 (en) 1999-03-12

Similar Documents

Publication Publication Date Title
AU732671B2 (en) Method of treatment and pharmaceutical composition
RU2292208C2 (en) New combination of anti-histamine agents having no sedative action with compounds effecting to leukotrien action for rhinitis/conjunctivitis treatment
EP2799071B1 (en) Levocetirizine and montelukast for the treatment of influenza and common cold
US20060004076A1 (en) Co-administration of dehydroepiandrosterone (DHEA) congener with pharmaceutically active agents for treating inflammation
US20210386677A1 (en) Delayed release deferiprone tablets and methods of using the same
BRPI0713933A2 (en) antihistamine syrups stable to sugar free storage
CA2660939A1 (en) Pharmaceutical compositions for the treatment of fungal infections
US8637087B2 (en) Treatment of interstitial cystitis using (6aR, 10aR)-Δ8-tetrahydrocannabinol-11-OIC acids
US20090163544A1 (en) Use of NK-3 Receptor Antagonists for the Treatment of Nausea and Vomiting
US6372197B1 (en) Methods and compositions using norastemizole in combination with leukotriene inhibitors
JP2003522121A (en) Use of riluzole for the treatment of multiple sclerosis
CA2328074A1 (en) Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors
US20070275996A1 (en) Use of Statins For The Treatment Of Metabolic Syndrome
US6902746B2 (en) Oral pharmaceutical compositions containing non-steroidal anti-inflammatory drugs and method for preparing the same
CA2180837C (en) Microgranules of 5-nitro imidazole derivatives
WO2022115481A1 (en) Methods and compositions for treating post-acute infection gastrointestinal disorders
CN113908162A (en) Application of acetamide derivative in preparation of medicine for preventing and treating Alzheimer's disease
CA3237151A1 (en) Methods and compositions for treating conditions associated with central hypoventilation
WO2001003701A1 (en) An oral composition having as a first active ingredient budesonide and as a second active ingredient an antibiotic, for use in intestinal conditions, especially crohn's disease
WO2001003703A1 (en) An oral composition having as a first active ingredient rofleponide and as a second active ingredient an antibiotic, for use in intestinal conditions, especially crohn's disease
JP2003521519A (en) Use of rofleponide in the treatment of irritable bowel syndrome
AU2007227286A1 (en) Treatment or prevention of scarring, capsular contractures and/or hyperpigmentation using leukotriene receptor antagonist and vitamin E
WO2000015226A1 (en) Antihistamines for treating non-infective sinusitis or otitis media

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired